Knowledge of normal gonadal hormone production and function provides the basis for understanding the ovarian pathologic effects resulting from perturbations in endocrine balance and feedback. A precisely timed, complex, and well-coordinated cascade of ovarian steroidogenesis accompanies normal cyclical follicular function. This cascade involves both estrogens and androgens. Alterations in the hormonal milieu are associated with specific morphological changes in the ovary. While predictable hormonal changes accompany commencement of menopause, several disease states are associated with ovarian dysfunction. These diseases include polycystic ovarian syndrome and hyperthecosis, both associated with androgenization. Ovarian tumors may also be associated with morphological and clinical alterations. While endocrinologically inert ovarian tumors are associated with morphologic evidence of stromal activation, endocrinologically active ovarian tumors may cause differentiation along either male or female lines as a consequence of differential productions of androgens and estrogens.
Introduction
Reproduction is a complex process involving interaction of the hypothalamus, pituitary, ovary, and the lower genital tract. The cyclic pattern of sex steroid production by the ovary is dramatically different from that of the testis. Testicular hormone production is independent of germ cells and remains relatively constant over the life-span of the individual, with only a slight decline beyond the sixth decade of life. By contrast, the reproductive cycle in women is critically dependent on the presence of ovarian follicles. As the number of oocytes in the ovary is fixed during embryonic life, a decline in ovarian function, termed the climacteric, is observed over a relatively short interval at the end of the reproductive life-span. While certainly not all ovarian pathology is associated with alterations in ovarian function, aberrations of the menstrual cycle and abnormal bleeding after menopause represent important clinical clues to the presence of ovarian pathology. Consequently, a thorough understanding of the physiology of gonadal hormone production is helpful in understanding ovarian pathology.
Gamete Physiology
Oocytes can only remain viable within the human ovary when they are enclosed by a complicated arrangement of supporting cells that are collectively termed the follicle. The follicle is composed of avascular granulosa cell layers in direct contact with the oocyte, a basement membrane surrounding the granulosa cells, and a vascularized thecal compartment. A functional relationship between the follicle and the surrounding ovarian stroma has never been proven, but the theca is thought to differentiate from the stroma. Table 1 depicts the fate of the follicles throughout a woman's life.
Germ cells migrate from the yolk sac into the primitive gonad in the first several months of embryonic life. At birth, there remain approximately 1 to 2 million follicles, indicating a high rate of atresia in these early primordial follicles. The cause for these early follicular losses is unknown.
Rapid atresia continues throughout childhood, and at puberty only 300,000 to 400,000 follicles remain. The increasing gonadotropin levels at puberty result in orderly follicular maturation and ovulation. By the end of the sixth decade of life, an occasional follicle remains, and the decline in ovarian hormone production, termed the climacteric, heralds the loss of reproductive potential. As only 300 to 400 oocytes are lost by the process of ovulation, the overwhelming majority of human oocytes are lost prior to full differentiation. As the lowest rate of atresia occurs during the reproductive years when levels of sex steroids and gonadotropins are high, the hormonal balance likely has a significant influence on the maintenance of these follicular structures.
Throughout history, the mean life expectancy of women has dramatically increased from 25 With the functional decline of the corpus luteum at the end of the luteal phase, there is a reduction in the negative feedback effect of gonadal steroids, increasing the levels of the circulating gonadotropins, primarily follicle-stimulating hormone (FSH). As a consequence, another cohort of follicles reaching that critical gonadotropin-dependent stage is recruited for the next cycle. FSH appears to be the key gonadotropin at this stage by virtue of its ability to induce aromatase activity in granulosa cells. Attainment of the ability to respond to FSH, i.e., the presence of functional FSH receptors, is probably the key event in that process. With an enhanced aromatase system, the granulosa cells produce large quantities of estradiol from thecally derived precursors and undergo active mitosis, the two principal characteristics of healthy follicles.
As humans are a monotocous species, follicle selection is necessary so that only a single follicle reaches preovulatory status each cycle. The process by which the other competing follicles are retarded in their maturation is unclear, but likely involves inhibition or loss of FSH responsiveness. Little is known of the dynamics of follicular steroidogenesis prior to follicle selection, as the quantity of steroids produced by all the compartments at that stage is small. In healthy follicles, the estrogen/androgen ratio is high, whereas androgen predominates in the follicular fluid of atretic follicles. This is consistent with the concept of FSH-induced aromatase activity being the critical step in avoiding the otherwise inevitable atresia.
The selection of a single dominant follicle culminates in high preovulatory estradiol levels. Estrogen and FSH synergize to induce luteinizing hormone (LH) receptors in the granulosa cells, preparing the follicle to respond to the mid-cycle surge of gonadotropins. LH is released in the largest amounts during the mid-cycle surge, causing a decline in aromatization and an increase in progesterone synthesis. This is obviously a well-coordinated event, optimizing the hormonal milieu for early embryonic events.
In understanding follicular steroidogenesis, it is important to divide the follicle into its basic components, the avascular granulosa compartment, the theca, and the ovarian stroma. Both the theca and ovarian stroma possess all the steroidogenic enzymes necessary to pro- As women enter the latter stages of their reproductive years, the steroid production by morphologically normal follicles declines. Simultaneously, FSH levels gradually rise, most prominently in the early follicular phase. It is unclear whether this is due to intrinsically unhealthy follicles that have not matured throughout the reproductive years or a necessity for a large number of follicles to be present. Eventually, a point is reached at which anovulatory cycles predominate, and atresia prior to ovulation is the rule. Estrogen without the opposition of progesterone predominates, and peripheral target organs are constantly exposed to estrogen. This climacteric interval covers the approximately 8 to 10 year span of declining ovarian function. As the estrogen levels decrease, eventually a point is reached at which menstruation ceases. The date of the last menstruation is termed the menopause, but represents only a highly identifiable clinical marker of the climacteric. After the climacteric, only stromal estrogen production remains and this is insufficient to maintain the peripheral estrogen target organs the steroid production by the ovarian stroma is low, and no obvious hypertrophy of the ovarian stroma is observed. A variety of disease states have been associated with ovarian failure, as listed in Table 2 .
The category of the "resistant ovary" is one in which histologically normal follicular structures are present, but apparently they are unresponsive to the circulating gonadotropins. This could be related to either defective gonadotropin synthesis or absent/nonfunctional ovarian gonadotropin receptors. In patients with an autoimmune basis for ovarian failure, an inflammatory process is usually present in the ovary. In all other circumstances of premature ovarian failure, the ovaries are morphologically indistinguishable from those of normal postmenopausal women (Plate 4).
Polycystic Ovary Syndrome
A unique syndrome of anovulation was identified in the 1930s and termed polycystic ovary syndrome. In this disease, multiple atretic follicles with active-appearing thecal compartments are present just under the ovarian capsule. The capsule itself is thickened and the ovarian stromal compartment is increased in size. The syndrome is clinically manifested by altered levels of circulating gonadotropins with an elevated LH to FSH ratio (greater than 3 versus a normal ratio of 1), hyperandrogenism manifested by elevated testosterone and androstenedione, and chronic unopposed estrogen effects on target organs. While this was originally thought to represent a single syndrome, it is now apparent that there are multiple subgroups, indistinguishable on clinical criteria. The morphology of the ovary in polycystic ovary syndrome appears to be a consequence of the anovulation with a large number of atretic follicles rather than any specific characteristic of the disease. Consequently, anything which alters gonadotropin levels and impedes follicular development results in this clinical syndrome.
The hypothalamic-pituitary axis in women with polycystic ovary syndrome is intact with operative negative and positive gonadotropin feedback function. The Congenital absence of the thymus 17-Hydroxylase deficiency Galactosemia aberrant gonadotropin profiles can be mimicked by excess androgen, whatever the source. Women with androgen-secreting tumors have been identified to have a histologic pattern consistent with polycystic ovary syndrome in the contralateral ovary. When their tumors are removed and their circulating androgens decline, the ovary reverts to normal both morphologically and functionally. A primary ovarian defect in polycystic ovary syndrome has also been postulated based on altered gonadotropin responsiveness. Theoretically, this could be due to an alteration in gonadotropin binding or inappropriate production of gonadotropin receptor regulatory proteins.
Compartmentalized ovarian hormone secretion has recently been investigated. It appears that in polycystic ovary syndrome, the ovarian androgens are produced primarily from the theca, and the large amounts of androgens are attributable to the large number of atretic follicles. During the atretic process, estrogen production by the granulosa cell compartment declines, but androgen and estrogen production by the theca is maintained. This results in the seemingly paradoxical situation of simultaneous androgen excess and chronic unopposed estrogen.
Despite the inability to ovulate, a follicular response to gonadotropins is still present. Treatment with both clomiphene citrate, whose action is mediated through the hypothalamus, and human menopausal gonadotropins, which act directly on the ovary, result in follicular development and ovulation. With the use of clomiphene citrate, the positive feedback effect of estrogen triggers the midcycle gonadotropin surge, whereas with exogenous gonadotropins, the spontaneous surge will not occur and hCG is used as a surrogate LH surge.
Isolated luteinized cells are observed scattered throughout the ovarian stroma in polycystic ovary syndrome. The term "luteinized cells" simply describes lipid-containing cells consistent morphologically with active steroidogenesis. Whether these are stromal cells responding to the altered gonadotropins or are remnants of the theca of previously atretic follicles is unknown.
Hyperthecosis
Hyperthecosis is a syndrome similar in clinical presentation to polycystic ovary syndrome, but the androgenization is more severe. While the circulating gonadotropin levels are similar, the testosterone concentrations are significantly higher, often overlapping the range usually seen with androgen-secreting ovarian tumors.
The term "hyperthecosis" is used because of the large number of steroidogenically active cells present in the ovarian stroma (Plate 5). These cells are indistinguishable in appearance from the luteinized cells present in the stroma of polycystic ovarian patients, except the number of cells is greater constituting large areas of the ovarian stroma. Reminiscent of the confusion with polycystic ovary syndrome, it is unclear whether these represent remnants of previous thecal compartments from follicles that have previously undergone atresia or are a unique thecal or stromal response. Similarly, their gonadotropin dependence is not known. The ovary is typically not as large as in polycystic ovary syndrome, as there is a smaller complement of atretic follicles. Consistent with that observation, it is much more difficult to stimulate ovulation in these women.
Stromal Activation by Ovarian Tumors
The association of endocrinologically inert ovarian tumors with clinical signs of sex steroid production has frequently been observed. Often, lipid-laden stromal cells are noted adjacent to the tumors in the remaining nontumorous ovarian stroma. These morphological changes have suggested activation of these surrounding stromal cells, with the observed clinical hormone production attributed to this presumed stromal steroidogenesis. Virtually any histologic tumor type can be present, including primary or metastatic ovarian cancer. Because of the difficulty in mechanically isolating these stromal cells, steroid production has never been experimentally verified but is likely on histologic criteria alone. The mechanism of this activation is unknown.
Endocrinologically Active Ovarian Tumors
When neoplastic, the gonadal stroma can differentiate along either male or female lines (Table 3 ). This includes Leydig and Sertoli cells that mimic male differentiation, and granulosa and thecal cells that yield female differentiation. It is not clear whether these represent analogous processes, as the granulosa and thecal cells are normally present within the ovary. Either one or both cell types in each category can be present, and rarely, both male and female cell types will be present in the same tumor (Plate 6). Although the majority of these tumors are benign, they can occasionally be malignant. Their major clinical importance is the peripheral consequences on the sex hormone target organs. Marked Any of these tumors can produce either androgens or estrogens, and the clinical presentation will reflect the particular steroid or steroids secreted. Those that differentiate along male lines tend to be androgen-secreting tumors, and those that differentiate along female lines tend to be estrogen-secreting tumors. Occasionally, both androgens and estrogens are secreted, and the women are simultaneously androgenized and estrogenized. A unique histologic marker for androgen production, regardless of the tumor cell type, is the intracellular crystaloid of Reinke.
The luteoma is an ovarian tumor, usually masculinizing, which is found only in pregnancy. It is typically yellow in color and histologically is composed of sheets of lipid-laden cells resembling a corpus luteum. It is not clear whether this is a true neoplasm or simply represents an exaggerated physiologic response of the ovarian stroma to hCG. Whether development of all these tumors is dependent on gonadotropins is unknown. As they generally respond with increased hormone output when given hCG, a relationship to gonadotropin stimulation remains an intriguing possibility. 
